Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity

Tania Løve Aaes(Ghent University), Agnieszka Kaczmarek(Ghent University), Tinneke Delvaeye(Ghent University), Bram De Craene(Ghent University), Stefaan De Koker(Ghent University), Liesbeth Heyndrickx(Ghent University), Iris Delrue(Ghent University), Joachim Taminau(Ghent University), Bartosz Wiernicki(Ghent University), Philippe De Groote(Ghent University), Abhishek D. Garg(KU Leuven), Luc Leybaert(Ghent University), Johan Grooten(Ghent University), Mathieu J.M. Bertrand(Ghent University), Patrizia Agostinis(KU Leuven), Geert Berx(Ghent University), Wim Declercq(Ghent University), Peter Vandenabeele(Ghent University), Dmitri V. Krysko(Ghent University)
Cell Reports
April 1, 2016
Cited by 446Open Access
Full Text

Abstract

Successful immunogenic apoptosis in experimental cancer therapy depends on the induction of strong host anti-tumor responses. Given that tumors are often resistant to apoptosis, it is important to identify alternative molecular mechanisms that elicit immunogenic cell death. We have developed a genetic model in which direct dimerization of FADD combined with inducible expression of RIPK3 promotes necroptosis. We report that necroptotic cancer cells release damage-associated molecular patterns and promote maturation of dendritic cells, the cross-priming of cytotoxic T cells, and the production of IFN-γ in response to tumor antigen stimulation. Using both FADD-dependent and FADD-independent RIPK3 induction systems, we demonstrate the efficient vaccination potential of immunogenic necroptotic cells. Our study broadens the current concept of immunogenic cell death and opens doors for the development of new strategies in cancer therapy.


Related Papers

No related papers found

Powered by citation graph analysis